Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 12/20 | 0.46 |
| ▸ | PPARA | Q07869 | 12/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262265 | 0.94 | PPARG (0.46) | TP53POLBPPARGPPARACYP2C9 | |
| SCHEMBL5439213 | 0.92 | PPARG (0.45) | TP53POLBPPARGPPARACYP2C9 | |
| SCHEMBL5260637 | 0.86 | PPARG (0.45) | TP53POLBPPARGPPARACYP2C9 | |
| SCHEMBL5226570 | 0.83 | PPARG (0.63) | TP53PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5262261 | 0.78 | PPARG (0.62) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5226585 | 0.76 | PPARA (0.44) | PPARGPPARAFFAR1 | |
| SCHEMBL5433693 | 0.76 | PPARG (0.59) | TP53POLBPPARGPPARACYP2C9 | |
| SCHEMBL5439211 | 0.76 | PPARG (0.61) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5223729 | 0.74 | PPARG (0.64) | PPARGPPARACYP2C9KCNH2FFAR1 | |
| SCHEMBL5224923 | 0.73 | PPARG (0.61) | PPARGPPARACYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | CRYSTAL GENOMICS, INC. (KR) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | SULT2A1, SPTLC2, SGMS2 | TP53 4759/4885POLB 4200/4885PPARG 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.